Novonesis: A Strong Performance in 2024 and an Optimistic Outlook for 2025
Wednesday, Feb 26, 2025 2:05 am ET
3min read 
Novonesis, a leading provider of sustainable biosolutions, has reported strong financial performance in 2024, with pro forma sales growth of 8% and an adjusted EBITDA margin of 36.1%. The company's CEO, Ester Baiget, expressed satisfaction with the overall performance, highlighting the strength of the company's well-diversified portfolio and its ability to address and leverage opportunities across industries and markets. Despite global instability, Novonesis is well-positioned to continue driving attractive organic sales growth and margin expansion in 2025.
NVX Basic Earnings per Share
| Name |
|---|
| Date |
| EBITDA |
| Total Revenue year-on-year growth value |
| Basic Earnings per Share(USD) |
| Total Revenue(USD) |
| NOVONIXNVX |
| 20240630 |
| -- |
| -- |
| -0.06 |
| -- |
The company's strong performance in 2024 was driven by several factors, including:
1. Organic sales growth: Novonesis achieved an 8% pro forma organic sales growth in 2024, with volumes increasing by ~6% and pricing contributing ~2%. Emerging markets grew by 12% organically, while developed markets increased by 6%.
2. Adjusted EBITDA margin: The pro forma adjusted EBITDA margin increased by 230bps to 36.1% in 2024, reflecting the company's operational efficiency and cost management strategies.
3. Cost synergies: The company's cost synergy strategy contributed approximately 1 percentage point (pp) on its pro forma adjusted EBITDA margin, at an 80% run rate of the 3-year EUR 80-90m target.
Looking ahead to 2025, Novonesis expects continued strong performance, with a relatively stronger first half. The company's outlook includes:
1. Pro forma organic sales growth: Novonesis expects pro forma organic sales growth to be at 5-8% (6-9% excluding the exit from certain countries), including sales synergies and pricing.
2. Adjusted EBITDA margin: The company anticipates an adjusted EBITDA margin of 37-38%, including significant growth re-investments.
Novonesis' strong financial performance in 2024 and its optimistic outlook for 2025 reflect the company's ability to execute strongly across the business, while also integrating two extraordinary companies and becoming Novonesis. The company's focus on sustainable biosolutions and its ability to address and leverage opportunities across industries and markets have contributed to its success and will likely continue to drive its growth in the future.
In conclusion, Novonesis' strong performance in 2024 and its optimistic outlook for 2025 demonstrate the company's ability to execute strongly across the business and its commitment to driving attractive organic sales growth and margin expansion. The company's focus on sustainable biosolutions and its ability to address and leverage opportunities across industries and markets have contributed to its success and will likely continue to drive its growth in the future.
_b905d9341749265671656.jpg)
Crypto is risky as many would say but I think the actual risk in Crypto is not investing, buying the capitulation isn't a tough call, but it is a very tough call to figure out what to do aside holding. I remember when I just got into crypto back in 2019 but later in 2020 I ended up selling it because I was dumb and I didn't understand it. I studied and learned and now I know how it works. Got back into crypto early in 2023 with 10k and I'm up with 128k in a short period of time Contact
@Matildafx
𝘰𝑛 ℎ𝑒𝑟 what’sapp 👉. +44 7778 958762
𝑓𝘰𝑟 𝑚𝘰𝑟𝑒 𝑔𝑢𝑖𝑑𝑎𝑛𝑐𝑒 𝑎𝑛𝑑 𝑖𝑛𝑓𝘰𝑟𝑚𝑎𝘵𝑖𝘰𝑛𝑠.